Tauriga Sciences, Inc.

TAUG

US87669X2053

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 02:32:26 2024-04-15 pm EDT			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	0.00%

2022	Tauriga Sciences Inc. Receives its 10,000th E-Commerce Order	CI
2022	Tauriga Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	CI

Tauriga Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021

November 15, 2021 at 04:37 pm EST

Tauriga Sciences, Inc. reported earnings results for the second quarter and six months ended September 30, 2021. For the second quarter, the company reported sales was USD 0.120101 million compared to USD 0.086355 million a year ago. Revenue was USD 0.107346 million compared to USD 0.07536 million a year ago. Net loss was USD 1.74 million compared to USD 0.642869 million a year ago. Basic loss per share from continuing operations was USD 0.006 compared to USD 0.004 a year ago. For the six months, sales was USD 0.165675 million compared to USD 0.170593 million a year ago. Revenue was USD 0.140713 million compared to USD 0.140164 million a year ago. Net loss was USD 2.57 million compared to USD 1.59 million a year ago. Basic loss per share from continuing operations was USD 0.009 compared to USD 0.01 a year ago.

Latest news about Tauriga Sciences, Inc.

Tauriga Sciences Inc. Receives its 10,000th E-Commerce Order	22-03-25	CI
Tauriga Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-16	CI
Tauriga Sciences Inc. Receives its 9,000th E-Commerce Order	22-01-21	CI
Tauriga Sciences Inc. Receives Product Endorsement from the State of Alaska	21-12-21	CI
Tauriga Sciences Inc. Formally Submits its Clinical Study Protocol to the Institutional Review Board	21-12-17	CI
Tauriga Sciences, Inc. Appoints Matthew A. Shaw as Member of its Corporate Advisory Board	21-12-01	CI
Tauriga Sciences, Inc. has Changed its Name to Sublingual Technologies Inc	21-11-22	CI
Tauriga Sciences, Inc. Confirms the Commercial Launch of Its New & Improved Tauri-Gummies? Product, Kosher Certified by Orthodox Union	21-11-16	CI
Tauriga Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-15	CI
Tauriga Sciences, Inc. to Proceed with the Production of Its Proprietary Kratom Infused Chewing Gum	21-11-02	CI
Tauriga Sciences Inc. Enters into Strategic Alliance with Psychedelic Water	21-10-19	CI
Tauriga Sciences Inc. Commences Development of Ashwagandha Infused Chewing Gum	21-10-15	CI
Tauriga Sciences Inc. Expands its Product Offerings of Delta 8 THC Infused Gummies	21-10-08	CI
Tauriga Sciences Inc. Commences Development of Kratom Extract Infused Chewing Gum	21-10-07	CI
Tauriga Sciences, Inc. Announces Resignation of David Wolitzky from the Board of Directors	21-09-22	CI
Tauriga Sciences Inc. Products Offerings Now Available on Amazon Prime	21-09-16	CI
Tauriga Sciences Inc. Completes Funding of the Study Protocol Phase of Its Recently Initiated Clinical Trial	21-09-13	CI
Tauriga Sciences Inc. Fully Repays its $135,000 Inventory Factoring Credit Facility	21-09-03	CI
Tauriga Sciences, Inc. Initiates Clinical Trial to Examine the Effects of Cannabidiol Doses on Pregnant Women with Diagnosis of Hyperemesis Gravidarum	21-08-31	CI
Tauriga Sciences, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2021	21-08-16	CI
Tauriga Sciences Inc. Announces the Arrival of Product Inventory for its Enhanced Tauri-Gum Product Line	21-08-03	CI
Tauriga Sciences Inc. Introduces Two Innovative Topical Products: CBD Infused Sunscreen Spray and Acai Fragrance Moisturizing Lip Balm	21-07-12	CI
Tauriga Sciences Inc. Introduces Two Innovative Topical Products: CBD Infused Sunscreen Spray and Acai Fragrance Moisturizing Lip Balm	21-07-12	CI
Tauriga Sciences Inc. Announces Availability of its Products for Sale on Amazon.com	21-07-09	CI
Tauriga Sciences, Inc. and Think BIG, LLC Confirm the Launch of Two Limited-Edition Frank White/Tauri-Gum Versions	21-07-09	CI

Chart Tauriga Sciences, Inc.

Duration

Period

More charts

Company Profile

Tauriga Sciences, Inc. is a science, technology and consumer products company. The Company operates through its subsidiary, Tauriga Pharma Corp., which is focused on the development of a pharmaceutical product line that is synergistic with the Companyâs primary Cannabidiol (CBD) product line. The Company operates through two segments. The first division consists of all retail, wholesale and e-commerce product sales of CBD/CBG Tauri-Gum, Tauri-Gummies, and other CBD/CBG products. The second segment is the research and development division, which consists of liabilities and results from any activity relative to the progress in the development of the Companyâs Food and Drug Administration (FDA) and Investigational New Drug (IND) application for Phase II Trial of its proposed pharmaceutical-grade version of Tauri-Gum. It also developed an immune booster version of Tauri-Gum chewing gum. This product contains 60 milligrams (mg) of Vitamin C and 10mg of Elemental Zinc per piece.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TAURIGA SCIENCES, INC.	0.00%	348
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals